Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCOCYTE CORPORATION

(OCX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
2.29(c) 2.21(c) 2.32(c) 2.4(c) 2.65(c) Last
276 698 483 791 480 014 285 694 426 350 Volume
+4.09% -3.49% +4.98% +3.45% +10.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 8,40 M - -
Net income 2021 -39,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,97x
Yield 2021 -
Sales 2022 17,7 M - -
Net income 2022 -41,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,05x
Yield 2022 -
Capitalization 244 M 244 M -
Capi. / Sales 2021 29,1x
Capi. / Sales 2022 13,8x
Nbr of Employees 51
Free-Float 89,8%
More Financials
Company
Oncocyte is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on development of a non-invasive confirmatory blood test... 
More about the company
Ratings of OncoCyte Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ONCOCYTE CORPORATION
12/08OncoCyte, Burning Rock Complete Second Part of Three-Part Technology Transfer
MT
12/08ONCOCYTE : and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled D..
PU
12/08ONCOCYTE CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
12/08Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled ..
AQ
12/06Oncocyte Corporation Hosting Business Update Call
AQ
12/02Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in T..
AQ
11/10Needham Cuts OncoCyte's Price Target to $7 From $8 on Lower Revenue Estimates; Buy Rati..
MT
11/09ONCOCYTE : Q3 Earnings Snapshot
AQ
11/09ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/09Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update - F..
PU
11/09Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
AQ
11/04Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction T..
PU
11/04ONCOCYTE CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
11/04Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction T..
AQ
11/04OncoCyte Corporation Announces the Clinical Launch of Determaio Immunotherapy Response ..
CI
More news
News in other languages on ONCOCYTE CORPORATION
12/08OncoCyte et Burning Rock concluent la deuxième partie d'un transfert de technologie en ..
10/27OncoCyte obtient un brevet américain couvrant une technologie de détection précoce du r..
09/20OncoCyte affirme que les données de l'essai ont montré le potentiel de DetermaIO en tan..
08/10Earnings Flash (OCX) ONCOCYTE CORPORATION annonce un chiffre d'affaires de 2 millions d..
07/15OncoCyte dépose une demande d'émission d'un maximum de 9,4 millions d'actions ordinaire..
More news
Analyst Recommendations on ONCOCYTE CORPORATION
More recommendations
Chart ONCOCYTE CORPORATION
Duration : Period :
OncoCyte Corporation Technical Analysis Chart | OCX | US68235C1071 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,65 $
Average target price 8,40 $
Spread / Average Target 217%
EPS Revisions
Managers and Directors
Ronald Asbury Andrews President, Chief Executive Officer & Director
Mitchell Stuart Levine Chief Financial Officer
Cavan M. Redmond Chairman
Douglas T. Ross Chief Science Officer
Gisela Paulsen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCOCYTE CORPORATION10.88%244
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531